Biomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy
mehr
Storys zum Thema Genetik
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Cells of the Future: A Key To Reprogramming Cell Identities
mehrNew Source of Stem Cells in Injury-Affected Brains of Patients
mehrFraunhofer-Institut für Produktionstechnologie IPT
Pooling expertise: Fraunhofer IPT and Harro Höfliger cooperate in the manufacturing of ATMP production systems
mehrBiomay Announces Expansion of GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services
mehrTechnische Universität München
Start-up dedicated to developing new antibiotics
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Smartbax nominated for Falling Walls award Start-up dedicated to developing new antibiotics • New approach against resistant pathogens • Agent damages protein transport and energy balance of bacteria • Two TUM spin-offs nominated for Science Breakthrough of the Year at Falling Walls Summit It all began with basic research: While conducting laboratory experiments, a team ...
mehr
Interpreting Large-Scale Medical Datasets: ScPoli Enables Multi-Scale Representations of Cells and Samples
The increasing amount of data recorded in medical research can only lead to scientific breakthroughs and essential therapies for patients if interpreted and analyzed correctly. Computer scientists at Helmholtz Munich developed a generative model named scPoli (single-cell population level integration), that performs ...
mehrPress Release: Exercise and Muscle Regulation: Implications for Diabetes and Obesity
How do our muscles respond at the molecular level to exercise? Researchers at Helmholtz Munich and the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) have unraveled the cellular basis and signaling pathways responsible for the p ositive impact of physical activity ...
mehrA New Ally in Fighting Brain Diseases: Our Very Own Skull
mehrWildDISCO: Visualizing Whole Bodies in Unprecedented Detail
mehrPotentiating Cancer Vulnerability to Ferroptosis: Off-Targeting Effects of DHODH Inhibitors
mehr- 2
CARAMBA: New Hope for Multiple Myeloma Patients
mehr
New Approach in Cancer Therapy With Innovative Mechanism-of-Action for Ferroptosis Induction
mehrRHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
mehrArtilysin® - A Groundbreaking "Green Pharma" Solution
mehr- 2
Study Reveals Influence of Urban Environment on Mental Health
mehr First Integrated Single-Cell Atlas of the Human Lung
Can a human organ be mapped on a single-cell level to learn about the functionality of each individual cell? And can we learn how different these cells are from person to person? Helmholtz Munich researchers and their collaborators have taken up this challenge and developed the Human Lung Cell Atlas using artificial intelligence (AI)-based techniques. This atlas elucidates the diversity of single lung cell types and ...
mehrDEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
mehr
DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
mehrAmicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows
mehrBjörn Cochlovius New CEO of Eleva / Seasoned Molecular Biologist and Entrepreneur Leads German Biotech Company into its Next Development
Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic proteins. The renowned oncologist, immunologist, and molecular biologist ...
mehrGrünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
mehr- 3
Sysmex Europe distributes MammaTyper®, an advanced breast cancer diagnostic assay, through the European distribution agreement with Cerca Biotech
mehr Technische Universität München
Genetically encoded nano-barcodes
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Electron microscopy: Nano-reporter proteins make invisible processes visible Genetically encoded nano-barcodes - New gene reporter system for electron microscopy - Uses barcodes to identify cellular states and structures that would otherwise remain unidentified - Important step to better elucidate cellular structural changes also in disease How do the nerve cells in our brain communicate with each other? What processes take place ...
mehr
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
BOSTON, LAUSANNE & LJUBLJANA, Slovenia (ots) - Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first approach Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
mehrMiltenyi Biotec acquires biosensor company lino Biotech
Zurich (ots) - lino Biotech, a leading biosensor company and the world’s only provider of Focal Molography, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023. Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy ...
mehrDEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
mehrEBiSC presents a new offering of iPSC-derived neurons
mehr
Vorherige1234567Nächste